A61K 9/2013
Organic compounds
Official title: {Organic compounds, e.g. phospholipids, fats}
A61K9/2013 (Organic compounds) appears on 4,477 US grants and 8,764 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,477
- Published applications
- 8,764
- Assignees
- 2,612
- Inventors
- 13,728
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 4 | 0 |
| 1978 | 3 | 0 |
| 1979 | 3 | 0 |
| 1980 | 6 | 0 |
| 1981 | 3 | 0 |
| 1982 | 6 | 0 |
| 1983 | 9 | 0 |
| 1984 | 11 | 0 |
| 1985 | 8 | 0 |
| 1986 | 15 | 0 |
| 1987 | 12 | 0 |
| 1988 | 16 | 0 |
| 1989 | 25 | 0 |
| 1990 | 17 | 0 |
| 1991 | 19 | 0 |
| 1992 | 24 | 0 |
| 1993 | 13 | 0 |
| 1994 | 14 | 0 |
| 1995 | 19 | 0 |
| 1996 | 33 | 0 |
| 1997 | 45 | 0 |
| 1998 | 47 | 0 |
| 1999 | 56 | 0 |
| 2000 | 63 | 0 |
| 2001 | 87 | 31 |
| 2002 | 51 | 113 |
| 2003 | 79 | 185 |
| 2004 | 55 | 215 |
| 2005 | 51 | 211 |
| 2006 | 49 | 223 |
| 2007 | 52 | 256 |
| 2008 | 47 | 267 |
| 2009 | 38 | 240 |
| 2010 | 76 | 308 |
| 2011 | 77 | 286 |
| 2012 | 113 | 270 |
| 2013 | 169 | 334 |
| 2014 | 229 | 428 |
| 2015 | 231 | 465 |
| 2016 | 252 | 465 |
| 2017 | 290 | 480 |
| 2018 | 222 | 386 |
| 2019 | 237 | 435 |
| 2020 | 261 | 457 |
| 2021 | 249 | 448 |
| 2022 | 244 | 495 |
| 2023 | 201 | 444 |
| 2024 | 244 | 456 |
| 2025 | 237 | 455 |
| 2026 | 156 | 411 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Tableting of specific polymer stabilizers6 Oct 2026US 12,751,926 B2BASF SE
- Dosage forms for TYK2 inhibitors6 Oct 2026US 12,751,948 B2Bristol-Myers Squibb Company
- Formulation for oral administration, comprising triazine derivative6 Oct 2026US 12,751,955 B2Shionogi & Co., Ltd.
- Combination drug for the control and management of type 2 diabetes mellitus6 Oct 2026US 12,751,958 B2Laboratorios Silanes S.A. de C.V.
- Oral formulations and uses thereof29 Sep 2026US 12,746,229 B2Inventisbio Co., Ltd.
- Pharmaceutical oral dosage form of q2038 Oct 2026US 2026/0306411 A1Qurient Co., Ltd.
- Triptolide formulations8 Oct 2026US 2026/0306412 A1Minneamrita Therapeutics LLC
- Compounds and combinations thereof for treating neurological and psychiatric conditions8 Oct 2026US 2026/0306426 A1Antecip Bioventures II LLC
- Method and pharmaceutical composition for treating a sleep disorder8 Oct 2026US 2026/0306442 A1Overseas Pharmaceuticals, Ltd.
- Formulations containing tryptamine derivatives and uses thereof8 Oct 2026US 2026/0306453 A1Psilera Inc.
Most cited
By later US patents
- Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms654US 8,499,966 B2AcelRx Pharmaceuticals, Inc. · 2013
- Controlled release oxycodone compositions466US 5,508,042 AEuro-Celtigue, S.A. · 1996
- Orally administrable opioid formulations having extended duration of effect437US 5,968,551 APurdue Pharma L. P. · 1999
- Controlled release oxycodone compositions436US 5,266,331 AEuroceltique, S.A. · 1993
- Controlled release oxycodone compositions411US 5,549,912 AEuro-Celtique S. A. · 1996